An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Camrelizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Jul 2022 Status changed from recruiting to completed.
- 20 May 2022 Results published in the BMC Cancer
- 19 Apr 2016 Status changed from not yet recruiting to recruiting.